Investors

Press Releases

 
Press Releases
  Date Title View
Dec 13, 2016
— Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies — — Long-term toxicology studies completed, confirming favorable safety profile of oral SCY-078 — ...
Dec 12, 2016
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic needs, today announced that the Company will participate in the Guggenheim Securities 4th Annual Boston Healthcare Conf...
Nov 7, 2016
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal  Activity and Favorable Safety Profile of  SCY-078 -- -- Company is Well Positioned and Capitalized to Accelerate and Expand Clinical Development of SCY-078 in Multiple Indications --...
Oct 25, 2016
SCY-078 demonstrates a low potential for certain drug-drug interactions — a relevant differentiator versus the azoles, the leading antifungal class — providing an opportunity for favorable labeling Significant step forward to further de-risk the ongoing development program of...
Oct 5, 2016
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida InfectionsWell-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis Patients...
Sep 20, 2016
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare Conference at the Sofitel New York Hotel on Tuesday, September 27, 2016 at 3:00 p.m. ET. A live webcast will ...
Aug 31, 2016
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor conferences: The Baird Global Healthcare Conference at the New York Palace Hotel on Wednesday, September 7, 2016 at 4:20 p.m...
Aug 24, 2016
JERSEY CITY, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's novel triterpenoid broad-spectrum antifungal agent, SCY-078,  for the treatment of invasive A...
Aug 8, 2016
 Positive Results from Two Phase 2 Studies Confirm Antifungal Clinical Activity of SCY-078  Company is Well Positioned and Capitalized to Advance its Clinical Programs Forward As Planned  JERSEY CITY, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Drug development compan...
Aug 4, 2016
JERSEY CITY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 11, 2016 at 2:00 p.m. ET. A live webcast will be available on the ...
FirstPrevious
3
... NextLast
= add release to Briefcase